Development of lactococcal GEM-based pneumococcal vaccines

Sandrine A. L. Audouy, Saskia van Selm, Maarten L. van Roosmalen, Eduard Post, Rolf Kanninga, Jolanda Neef, Silvia Estevao, Edward E. S. Nieuwenhuis, Peter V. Adrian, Kees Leenhouts, Peter W. M. Hermans*

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

86 Citaten (Scopus)

Samenvatting

We report the development of a novel protein-based nasal vaccine against Streptococcus pneumoniae, in which three pneumococcal proteins were displayed on the surface of a non-recombinant, killed Lactococcus lactis-derived delivery system, called Gram-positive Enhancer Matrix (GEM). The GEM particles induced the production of the proinflammatory cytokine tumour necrosis factor-alpha (TNF-alpha) by macrophages as well as the maturation of dendritic cells. The pneumococcal proteins IgA1 protease (IgA1p), putative proteinase maturation protein A (PpmA) and streptococcal lipoprotein A (SlrA) were anchored in trans to the surface of the GEM particles after recombinant production of the antigens in L. lactis as hybrids with a lactococcal cell wall binding domain, named Protein Anchor domain (PA). Intranasal immunisation with the SlrA-IgAlp or trivalent vaccine combinations without additional adjuvants showed significant protection against fatal pneumococcal pneumonia in mice. The GEM-based trivalent vaccine is a potential pneumococcal vaccine candidate that is expected to be easy to administer, safe and affordable to produce. (C) 2006 Elsevier Ltd. All rights reserved.

Originele taal-2English
Pagina's (van-tot)2497-2506
Aantal pagina's10
TijdschriftVaccine
Volume25
Nummer van het tijdschrift13
DOI's
StatusPublished - 22-mrt.-2007
Evenement5th International Symposium on Pneumococci and Pneumococcal Diseases - , Australia
Duur: 2-apr.-20066-apr.-2006

Citeer dit